

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 12:52:43 ON 22 JAN 2008
FILE 'CAPLUS' ENTERED AT 12:52:43 ON 22 JAN 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	11.35	259.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.60	-1.60

=> file registry

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	11.35	259.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.60	-1.60

FILE 'REGISTRY' ENTERED AT 12:52:56 ON 22 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JAN 2008 HIGHEST RN 1000370-19-3
DICTIONARY FILE UPDATES: 21 JAN 2008 HIGHEST RN 1000370-19-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10571733.str



```

chain nodes :
19 20 21 22 23 24 25 26
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
1-24 6-19 8-19 12-20 14-20 16-21 17-22 18-23 24-25 25-26
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
exact/norm bonds :
6-19 8-19 12-20 14-20 24-25 25-26
exact bonds :
1-24 16-21 17-22 18-23
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS

```

L5 STRUCTURE UPLOADED

=> l5 sss ful

L5 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s l5 sss ful

FULL SEARCH INITIATED 12:53:21 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 66 TO ITERATE

100.0% PROCESSED 66 ITERATIONS

5 ANSWERS


SEARCH TIME: 00.00.01

L6

5 SEA SSS FUL L5

=> d 16 1-6


L6 ANSWER 1 OF 5 REGISTRY COPYRIGHT 2008 ACS on STN
RN 848468-37-1 REGISTRY
ED Entered STN: 14 Apr 2005
CN Benzenesulfonamide, N-propyl-2-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)
MF C22 H27 N5 O5 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L6 ANSWER 2 OF 5 REGISTRY COPYRIGHT 2008 ACS on STN
RN 848468-35-9 REGISTRY
ED Entered STN: 14 Apr 2005
CN Benzenesulfonamide, N,N-dimethyl-2-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)
MF C21 H25 N5 O5 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L6 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2008 ACS on STN
RN 848468-34-8 REGISTRY
ED Entered STN: 14 Apr 2005
CN Benzenesulfonamide, N-(2-hydroxyethyl)-2-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)
MF C21 H25 N5 O6 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L6 ANSWER 4 OF 5 REGISTRY COPYRIGHT 2008 ACS on STN
RN 604802-45-1 REGISTRY
ED Entered STN: 15 Oct 2003
CN Benzenesulfonamide, N,2-dimethyl-6-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)
MF C21 H25 N5 O5 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L6 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2008 ACS on STN
RN 604802-41-7 REGISTRY
ED Entered STN: 15 Oct 2003
CN Benzenesulfonamide, N-methyl-2-[[5-(trifluoromethyl)-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)
MF C21 H22 F3 N5 O5 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	188.82	448.39
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.60

FILE 'CAPLUS' ENTERED AT 12:53:50 ON 22 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Jan 2008 VOL 148 ISS 4
FILE LAST UPDATED: 21 Jan 2008 (20080121/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 16

L7 2 L6


=> d 17 ibib abs 1-2

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:260035 CAPLUS
DOCUMENT NUMBER: 142:336377
TITLE: Preparation of 2,4-di(phenylamino)pyrimidines useful in the treatment of proliferative disorders
INVENTOR(S): Imbach, Patricia; Roesel, Johannes

PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma GmbH
 SOURCE: PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005026130	A1	20050324	WO 2004-EP10466	20040917
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004272288	A1	20050324	AU 2004-272288	20040917
CA 2538413	A1	20050324	CA 2004-2538413	20040917
EP 1663992	A1	20060607	EP 2004-765358	20040917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1852900	A	20061025	CN 2004-80026942	20040917
BR 2004014544	A	20061107	BR 2004-14544	20040917
JP 2007505858	T	20070315	JP 2006-526595	20040917
US 2007105839	A1	20070510	US 2006-571733	20060314
IN 2006CN00922	A	20070615	IN 2006-CN922	20060316
MX 2006PA03054	A	20060531	MX 2006-PA3054	20060317
PRIORITY APPLN. INFO.:			US 2003-504374P	P 20030918
			WO 2004-EP10466	W 20040917

OTHER SOURCE(S): CASREACT 142:336377; MARPAT 142:336377
 GI



AB The title compds. I [X = CR₀, N; R₀, R₁-R₄ = H, OH, alkyl, etc.; or R₃ and R₄ form together with the nitrogen and carbon atoms to which they are attached a 5-10 membered heterocyclic ring and comprising addnl. 1-3 heteroatoms selected from N, O and S; or R₁-R₃ = halo, haloalkyl, alkoxy, etc.; or R₁ and R₂ form aryl or 5-10 membered heteroaryl; R₅, R₆ = H, halo, CN, alkyl, etc.; R₇-R₉ = H, OH, alkyl, etc.], useful for preventing or treating proliferative disorders such as a tumor disease, by inhibiting ALK activity, were prepared E.g., a 2-step synthesis of 2-[2-(1H-indazol-6-ylamino)-pyrimidin-4-ylamino]benzenesulfonamide, starting from 2-aminobenzenesulfonamide and 2,4-dichloropyrimidine, was given. The compds. I were tested for inhibition of ALK tyrosine kinase in various cellular assays (data were given for representative compds. I).

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:757684 CAPLUS

DOCUMENT NUMBER: 139:292258

TITLE: Pyrimidine derivatives

INVENTOR(S): Baenteli, Rolf; Zenke, Gerhard; Cooke, Nigel Graham; Duthaler, Rudolf; Thoma, Gebhard; Von Matt, Anette; Honda, Toshiyuki; Matsuura, Naoko; Nonomura, Kazuhiko; Ohmori, Osamu; Umemura, Ichiro; Hinterding, Klaus; Papageorgiou, Christos

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SOURCE: PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003078404	A1	20030925	WO 2003-EP2710	20030314
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2479133	A1	20030925	CA 2003-2479133	20030314
AU 2003227070	A1	20030929	AU 2003-227070	20030314
AU 2003227070	B2	20070201		
EP 1487805	A1	20041222	EP 2003-744366	20030314
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008461	A	20050118	BR 2003-8461	20030314
JP 200527529	T	20050915	JP 2003-576410	20030314
CN 1697830	A	20051116	CN 2003-806101	20030314
NZ 535109	A	20060526	NZ 2003-535109	20030314
IN 2004CN02025	A	20060224	IN 2004-CN2025	20040910
MX 2004PA09058	A	20050125	MX 2004-PA9058	20040915
NO 2004004374	A	20041014	NO 2004-4374	20041014
US 2006100227	A1	20060511	US 2005-507060	20050613
ZA 200406709	A	20060531	ZA 2004-6709	20060330
PRIORITY APPLN. INFO.:			GB 2002-6215	A 20020315
			WO 2003-EP2710	W 20030314

OTHER SOURCE(S): MARPAT 139:292258

GI



I

AB The pyrimidine derivs. (I) are claimed, wherein X = =CR or =N, R, R1, R2, R3, R4 independently is H, OH, C1-8alkyl, C2-8alkenyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-8alkyl, hydroxyC1-8alkyl, C1-8alkoxyC1-8alkyl, hydroxyC1-8alkoxyC1-8alkyl, arylC1-8alkyl which optionally may be substituted on the ring by OH, C1-8alkoxy, carboxy, C1-8alkoxycarbonyl or R3 and R4 form together with N and C atoms to which they are attached to a 5-10 membered heterocyclic ring containing 1, 2 or 3 heteroatoms of N, O or S; R1 and R2 form together with C atoms to which they are attached aryl of 5-10 membered heteroaryl moiety containing 1-2 heteroatoms of N, O, S; R and R6 independently is H, halo, CN, C1-8alkyl, haloC1-8alkyl, C2-8alkenyl, C2-8alkynyl, C3-8cycloalkyl, C3-8cycloalkylC1-8alkyl, C5-10arylC1-8alkyl,; R7, R8 and R9 is independently H, OH, C1-8alkyl, C2-8alkenyl, haloC1-8alkyl, C1-8alkoxy, C3-8cycloalkyl, C3-8cycloalkylC1-8, arylC1-8alkyl. disorders where ZAP-70 and/or Syk inhibition plays a role or caused by a malfunction of signal cascades connected with FAK. I are useful in disorders where ZAP-70 and/or Syk inhibition plays a role or caused by a malfunction of signal cascades connected with FAK. Pharmaceutical compns. containing I are claimed.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 11:53:56 ON 22 JAN 2008)

FILE 'REGISTRY' ENTERED AT 11:54:20 ON 22 JAN 2008

L1 STRUCTURE UPLOADED

L2 0 S L1 FAM FUL

L3 5 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 11:55:10 ON 22 JAN 2008

L4 2 S L3

FILE 'REGISTRY' ENTERED AT 12:52:56 ON 22 JAN 2008

L5 STRUCTURE UPLOADED

L6 5 S L5 SSS FUL

FILE 'CAPLUS' ENTERED AT 12:53:50 ON 22 JAN 2008

L7 2 S L6

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
8.22	456.61

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-1.60	-3.20

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 12:56:45 ON 22 JAN 2008